Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug 27:4:233.
doi: 10.3389/fonc.2014.00233. eCollection 2014.

Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future

Johanna N Spaans  1 , Glenwood D Goss  2
Affiliations
Review

Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future

Johanna N Spaans et al. Front Oncol. .

Abstract

Molecularly targeted agents are changing the therapeutic landscape in advanced non-small cell lung cancer. Since the discovery of sensitizing mutations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) domain, clinical investigations have focused on optimizing the efficacy of EGFR and ALK tyrosine kinase inhibitors by addressing therapeutic resistance that commonly develops within a year of treatment initiation. Here, we review the clinical trials of novel therapies and combination regimens that have been undertaken in response to our evolving understanding of the mechanisms of resistance to targeted therapy. The aim of these trials was to enhance the therapeutic efficacy of targeted therapies by improving blockade and/or inhibiting parallel or compensatory signaling pathways. We have documented the sequential conduct of EGFR and ALK biomarker-driven trials in order to highlight particular pitfalls and successes, which should be considered in the design of future trials. Although there remain significant challenges, substantial gains have been made in our understanding of cellular resistance. This knowledge will drive the design of future trials to the benefit of lung cancer patients.

Keywords: ALK; EGFR; clinical trial; molecular therapy; resistance.

PubMed Disclaimer

References

    1. World Health Organization. Factsheet No 310: The Top Ten Causes of Death (2008). Available from: http://www.who.int/mediacentre/factsheets/fs310_2008.pdf
    1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta, GA: American Cancer Society, Inc; (2009).
    1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell-lung-cancer. N Engl J Med (2002) 346:92–810.1056/NEJMoa011954 - DOI - PubMed
    1. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, et al. Impact of EGFR inhibitor in non-small cell lung cancer on prognosis-free and overall survival: a meta-analysis. J Natl Cancer Inst (2013) 105(9):595–60510.1093/jnci/djt072 - DOI - PubMed
    1. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Treatment with therapies matched to oncogenic drivers improves survival in patients with lung cancers: results from the lung cancer mutation consortium (LCMC). J Thorac Oncol (2013) 8(2):S3–410.1001/jama.2014.3741 - DOI - PMC - PubMed